Research progress on the activation of complement system is involved in the pathogenesis of Alzheimer's disease

doi:10.11958/20231554

Abstract

Abstract:

Alzheimer's disease (AD) is a common neurodegenerative disease, which is mainly caused by brain lesions. The activation of complement system plays an important role in the process of AD lesions. The activated complement can bind to cell membrane receptors and regulate downstream signals. Therefore, inhibiting complement activation provides a new idea for AD treatment. This article reviews the progress in the mechanism and drug development of complement activation in AD, which may provide a new perspective for the diagnosis, treatment and drug development of AD.

Key words: Alzheimer disease, complement system proteins, amyloid beta-peptides, synapses, tau proteins, colloid cell, neuroinflammation

CLC Number:

R745.7

References 41

[1]	邵蕊, 李岱, 韩召利, 等. 基于老年综合评估的个体化康复训练对阿尔茨海默病患者认知功能、风险防范的影响[J]. 天津医药, 2021, 49(8):847-851.
	SHAO R, LI D, HAN Z L, et al. Effects of individualized rehabilitation training based on comprehensive geriatric assessment on cognitive function and risk prevention of patients with Alzheimer's disease[J]. Tianjin Med J, 2021, 49(8):847-851. doi:10.11958/20210643.
[2]	YANG J, WISE L, FUKUCHI K I. TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer's disease[J]. Front Immunol, 2020, 11:724. doi:10.3389/fimmu.2020.00724.
[3]	YIN C, ACKERMANN S, MA Z, et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q[J]. Nat Med, 2019, 25(3):496-506. doi:10.1038/s41591-018-0336-8.
[4]	SHAH A, KISHORE U, SHASTRI A. Complement system in Alzheimer's disease[J]. Int J Mol Sci, 2021, 22(24):13647. doi:10.3390/ijms222413647.
[5]	FATOBA O, ITOKAZU T, YAMASHITA T. Complement cascade functions during brain development and neurodegeneration[J]. FEBS J, 2022, 289(8):2085-2109. doi:10.1111/febs.15772.
[6]	CHEN W T, LU A, CRAESSAERTS K, et al. Spatial transcriptomics and in situ sequencing to study Alzheimer's disease[J]. Cell, 2020, 182(4):976-991.e19. doi:10.1016/j.cell.2020.06.038.
[7]	WU T, DEJANOVIC B, GANDHAM V D, et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy[J]. Cell Rep, 2019, 28(8):2111-2123.e6. doi:10.1016/j.celrep.2019.07.060.
[8]	LIAN H, YANG L, COLE A, et al. NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease[J]. Neuron, 2015, 85(1):101-115. doi:10.1016/j.neuron.2014.11.018.
[9]	LITVINCHUK A, WAN Y W, SWARTZLANDER D B, et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer's disease[J]. Neuron, 2018, 100(6):1337-1353.e5. doi:10.1016/j.neuron.2018.10.031.
[10]	ZHANG D F, FAN Y, XU M, et al. Complement C7 is a novel risk gene for Alzheimer's disease in Han Chinese[J]. Natl Sci Rev, 2019, 6(2):257-274. doi:10.1093/nsr/nwy127.
[11]	YUAN H, DU L, GE P. Complement receptor 1 genetic polymorphism contributes to sporadic Alzheimer's disease susceptibility in Caucasians: a meta-analysis[J]. Biosci Rep, 2020, 40(6):BSR20200321. doi:10.1042/BSR20200321.
[12]	MAHMOUDI R, FELDMAN S, KISSERLI A, et al. Inherited and acquired decrease in complement receptor 1(CR1)density on red blood cells associated with high levels of soluble CR1 in Alzheimer's disease[J]. Int J Mol Sci, 2018, 19(8):2175. doi:10.3390/ijms19082175.
[13]	CAI H, PANG Y, WANG Q, et al. Proteomic profiling of circulating plasma exosomes reveals novel biomarkers of Alzheimer's disease[J]. Alzheimers Res Ther, 2022, 14(1):181. doi:10.1186/s13195-022-01133-1.
[14]	GOETZL E J, SCHWARTZ J B, ABNER E L, et al. High complement levels in astrocyte-derived exosomes of Alzheimer disease[J]. Ann Neurol, 2018, 83(3):544-552. doi:10.1002/ana.25172.
[15]	NOGUERAS-ORTIZ C J, MAHAIRAKI V, DELGADO-PERAZA F, et al. Astrocyte- and neuron-derived extracellular vesicles from Alzheimer's disease patients effect complement-mediated neurotoxicity[J]. Cells, 2020, 9(7):1618. doi:10.3390/cells9071618.
[16]	FLORENTINUS-MEFAILOSKI A, BOWDEN P, SCHELTENS P, et al. The plasma peptides of Alzheimer's disease[J]. Clin Proteomics, 2021, 18(1):17. doi:10.1186/s12014-021-09320-2.
[17]	BONHAM L W, DESIKAN R S, YOKOYAMA J S, et al. The relationship between complement factor C3,APOE ε4,amyloid and tau in Alzheimer's disease[J]. Acta Neuropathol Commun, 2016, 4(1):65. doi:10.1186/s40478-016-0339-y.
[18]	LU G, LIU W, HUANG X, et al. Complement factor H levels are decreased and correlated with serum C-reactive protein in late-onset Alzheimer's disease[J]. Arq Neuropsiquiatr, 2020, 78(2):76-80. doi:10.1590/0004-282X20190151.
[19]	王翠, 杨畅, 金玉, 等. 木犀草苷对阿尔茨海默病模型细胞凋亡和炎性因子表达的研究[J]. 天津医药, 2023, 51(7):701-706.
	WANG C, YANG C, JIN Y, et al. Study of cynaroside on apoptosis and expression of inflammatory factor in model cells of Alzheimer's disease[J]. Tianjin Med J, 2023, 51(7):701-706. doi:10.11958/20221922.
[20]	CHERNYAEVA L, RATTI G, TEIRILÄ L, et al. Reduced binding of ApoE4 to complement factor H promotes amyloid-β oligomerization and neuroinflammation[J]. EMBO Rep, 2023, 24(7):e56467. doi:10.15252/embr.202256467.
[21]	BISHT K, SHARMA K, TREMBLAY M È. Chronic stress as a risk factor for Alzheimer's disease:Roles of microglia-mediated synaptic remodeling,inflammation,and oxidative stress[J]. Neurobiol Stress, 2018, 9:9-21. doi:10.1016/j.ynstr.2018.05.003.
[22]	ROY E R, WANG B, WAN Y W, et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease[J]. J Clin Invest, 2020, 130(4):1912-1930. doi:10.1172/JCI133737.
[23]	LIAN H, LITVINCHUK A, CHIANG A C, et al. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer's disease[J]. J Neurosci, 2016, 36(2):577-589. doi:10.1523/JNEUROSCI.2117-15.2016.
[24]	GUAN P P, GE T Q, WANG P. As a potential therapeutic target,C1q induces synapse loss via inflammasome-activating apoptotic and mitochondria impairment mechanisms in Alzheimer's disease[J]. J Neuroimmune Pharmacol, 2023, 18(3):267-284. doi:10.1007/s11481-023-10076-9.
[25]	AN X Q, XI W, GU C Y, et al. Complement protein C5a enhances the β-amyloid-induced neuro-inflammatory response in microglia in Alzheimer's disease[J]. Med Sci(Paris), 2018,34 Focus issue F1:116-120. doi:10.1051/medsci/201834f120.
[26]	KRETZSCHMAR G C, BUMILLER-BINI V, GASPARETTO FILHO M A, et al. Neutrophil extracellular traps:A perspective of neuroinflammation and complement activation in Alzheimer's disease[J]. Front Mol Biosci, 2021, 8:630869. doi:10.3389/fmolb.2021.630869.
[27]	HAO X, LI Z, LI W, et al. Periodontal infection aggravates c1q-mediated microglial activation and synapse pruning in Alzheimer's mice[J]. Front Immunol, 2022, 13:816640. doi:10.3389/fimmu.2022.816640.
[28]	WANG C, YUE H, HU Z, et al. Microglia mediate forgetting via complement-dependent synaptic elimination[J]. Science, 2020, 367(6478):688-694. doi:10.1126/science.aaz2288.
[29]	QIN Q, WANG M, YIN Y, et al. The Specific mechanism of TREM2 regulation of synaptic clearance in Alzheimer's disease[J]. Front Immunol, 2022, 13:845897. doi:10.3389/fimmu.2022.845897.
[30]	SPURRIER J, NICHOLSON L, FANG X T, et al. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q[J]. Sci Transl Med, 2022, 14(647):eabi8593. doi:10.1126/scitranslmed.abi8593.
[31]	CARPANINI S M, TORVELL M, BEVAN R J, et al. Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models[J]. Acta Neuropathol Commun, 2022, 10(1):99. doi:10.1186/s40478-022-01404-w.
[32]	LEE H E, LIM D, LEE J Y, et al. Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease[J]. Future Med Chem, 2019, 11(15):1845-1848. doi:10.4155/fmc-2019-0151.
[33]	HU J, YANG Y, WANG M, et al. Complement C3a receptor antagonist attenuates tau hyperphosphorylation via glycogen synthase kinase 3β signaling pathways[J]. Eur J Pharmacol, 2019, 850:135-140. doi:10.1016/j.ejphar.2019.02.020.
[34]	YAO Y, CHANG Y, LI S, et al. Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice[J]. Brain Res Bull, 2023, 200:110685. doi:10.1016/j.brainresbull.2023.110685.
[35]	JUN G R, YOU Y, ZHU C, et al. Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's disease[J]. Alzheimers Dement, 2022, 18(11):2042-2054. doi:10.1002/alz.12607.
[36]	JEVTIC S, SENGAR A S, SALTER M W, et al. The role of the immune system in Alzheimer disease:Etiology and treatment[J]. Ageing Res Rev, 2017, 40:84-94. doi:10.1016/j.arr.2017.08.005.
[37]	HANSEN D V, HANSON J E, SHENG M. Microglia in Alzheimer's disease[J]. J Cell Biol, 2018, 217(2):459-472. doi:10.1083/jcb.201709069.
[38]	LANDLINGER C, OBERLEITNER L, GRUBER P, et al. Active immunization against complement factor C5a:A new therapeutic approach for Alzheimer's disease[J]. J Neuroinflammation, 2015, 12:150. doi:10.1186/s12974-015-0369-6.
[39]	DEJANOVIC B, HUNTLEY M A, DE MAZIÈRE A, et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies[J]. Neuron, 2018, 100(6):1322-1336.e7. doi:10.1016/j.neuron.2018.10.014.
[40]	HETTMANN T, GILLIES S D, KLEINSCHMIDT M, et al. Development of the clinical candidate PBD-C06,a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation[J]. Sci Rep, 2020, 10(1):3294. doi:10.1038/s41598-020-60319-5.
[41]	CHEN H, DENG C, MENG Z, et al. Effects of catalpol on Alzheimer's disease and its mechanisms[J]. Evid Based Complement Alternat Med, 2022,2022:2794243. doi:10.1155/2022/2794243.